InBody Co.,Ltd (041830.KQ)
KRW 24150.0
(-0.21%)
KRW 24150.0
(-0.21%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 24.62 Billion KRW | -7.53% |
| 2022 | 26.62 Billion KRW | 33.28% |
| 2021 | 19.97 Billion KRW | 25.11% |
| 2020 | 15.96 Billion KRW | 5.94% |
| 2019 | 15.07 Billion KRW | 110.71% |
| 2018 | 7.15 Billion KRW | 29.87% |
| 2017 | 5.5 Billion KRW | 16.54% |
| 2016 | 4.72 Billion KRW | -22.63% |
| 2015 | 6.1 Billion KRW | 80.0% |
| 2014 | 3.39 Billion KRW | 76.92% |
| 2013 | 1.91 Billion KRW | -5.42% |
| 2012 | 2.02 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 33.05 Billion KRW | -23.86% |
| 2024 Q1 | 43.41 Billion KRW | 76.34% |
| 2023 Q4 | 24.62 Billion KRW | -13.86% |
| 2023 FY | 24.62 Billion KRW | -7.53% |
| 2023 Q1 | 32.01 Billion KRW | 20.23% |
| 2023 Q2 | 28.32 Billion KRW | -11.5% |
| 2023 Q3 | 28.58 Billion KRW | 0.9% |
| 2022 FY | 26.62 Billion KRW | 33.28% |
| 2022 Q4 | 26.62 Billion KRW | 3.01% |
| 2022 Q3 | 25.84 Billion KRW | 6.29% |
| 2022 Q2 | 24.31 Billion KRW | -5.32% |
| 2022 Q1 | 25.68 Billion KRW | 28.56% |
| 2021 Q1 | 20.49 Billion KRW | 28.33% |
| 2021 Q3 | 21.89 Billion KRW | 3.2% |
| 2021 Q4 | 19.97 Billion KRW | -8.76% |
| 2021 Q2 | 21.21 Billion KRW | 3.53% |
| 2021 FY | 19.97 Billion KRW | 25.11% |
| 2020 Q2 | 14.94 Billion KRW | 0.49% |
| 2020 FY | 15.96 Billion KRW | 5.94% |
| 2020 Q3 | 17.24 Billion KRW | 15.39% |
| 2020 Q1 | 14.87 Billion KRW | -1.31% |
| 2020 Q4 | 15.96 Billion KRW | -7.43% |
| 2019 Q4 | 15.07 Billion KRW | -7.84% |
| 2019 FY | 15.07 Billion KRW | 110.71% |
| 2019 Q3 | 16.35 Billion KRW | 50.94% |
| 2019 Q2 | 10.83 Billion KRW | -24.58% |
| 2019 Q1 | 14.36 Billion KRW | 142.59% |
| 2018 Q1 | 8.98 Billion KRW | 80.39% |
| 2018 Q4 | 5.92 Billion KRW | -55.72% |
| 2018 FY | 7.15 Billion KRW | 29.87% |
| 2018 Q2 | 22.26 Billion KRW | 147.97% |
| 2018 Q3 | 13.37 Billion KRW | -39.93% |
| 2017 FY | 5.5 Billion KRW | 16.54% |
| 2017 Q4 | 4.97 Billion KRW | -46.65% |
| 2017 Q3 | 9.33 Billion KRW | 38.3% |
| 2017 Q1 | 6.85 Billion KRW | 66.52% |
| 2017 Q2 | 6.74 Billion KRW | -1.52% |
| 2016 Q4 | 4.11 Billion KRW | -26.73% |
| 2016 FY | 4.72 Billion KRW | -22.63% |
| 2016 Q2 | 8.26 Billion KRW | -26.58% |
| 2016 Q1 | 11.25 Billion KRW | 89.68% |
| 2016 Q3 | 5.61 Billion KRW | -32.06% |
| 2015 Q3 | 6.92 Billion KRW | -0.26% |
| 2015 Q1 | 11.48 Billion KRW | 238.28% |
| 2015 FY | 6.1 Billion KRW | 80.0% |
| 2015 Q4 | 5.93 Billion KRW | -14.3% |
| 2015 Q2 | 6.94 Billion KRW | -39.53% |
| 2014 Q3 | 4.48 Billion KRW | 3.6% |
| 2014 Q4 | 3.39 Billion KRW | -24.34% |
| 2014 Q2 | 4.33 Billion KRW | 3.26% |
| 2014 Q1 | 4.19 Billion KRW | 118.59% |
| 2014 FY | 3.39 Billion KRW | 76.92% |
| 2013 Q2 | 2.89 Billion KRW | -9.27% |
| 2013 Q4 | 1.91 Billion KRW | -40.37% |
| 2013 FY | 1.91 Billion KRW | -5.42% |
| 2013 Q1 | 3.19 Billion KRW | 57.45% |
| 2013 Q3 | 3.21 Billion KRW | 11.02% |
| 2012 Q3 | 1.26 Billion KRW | 0.0% |
| 2012 FY | 2.02 Billion KRW | 0.0% |
| 2012 Q4 | 2.02 Billion KRW | 59.72% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Osang Healthcare Co.,Ltd | 27.25 Billion KRW | 9.667% |
| Curexo Inc. | 6.94 Billion KRW | -254.719% |
| Seegene, Inc. | 221.05 Billion KRW | 88.862% |
| i-SENS, Inc. | 195.32 Billion KRW | 87.394% |
| Ray Co., Ltd. | 128.35 Billion KRW | 80.818% |
| Gencurix Inc. | 21.49 Billion KRW | -14.525% |
| Sugentech Inc. | 20.73 Billion KRW | -18.759% |
| L&C Bio Co., Ltd | 105.37 Billion KRW | 76.635% |